Cargando…

Atezolizumab-induced Autoimmune Diabetes in a Patient with Metastatic Breast Cancer: A Case Report

INTRODUCTION: Immune checkpoint inhibitors (ICI) are a class of immunotherapy drugs used increasingly in the treatment of multiple types of cancer. Major side effects include immune-related adverse effects, potentially resulting in damage to normal tissue across multiple different organ systems. CAS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clontz, Robert, Dang, Duc M., Hieger, Michelle A., Becker, Brent A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	University of California Irvine, Department of Emergency Medicine publishing Western Journal of Emergency Medicine 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143823/ https://www.ncbi.nlm.nih.gov/pubmed/34437002 http://dx.doi.org/10.5811/cpcem.2021.2.51508

Ejemplares similares

Atezolizumab-Induced Autoimmune Diabetes in a Patient With Metastatic Lung Cancer
por: Sothornwit, Jin, et al.
Publicado: (2019)

Skin autoimmunity might be associated with increased efficacy of atezolizumab in metastatic urothelial carcinoma: a case report
por: Rkman, Deni, et al.
Publicado: (2019)

Atezolizumab-associated encephalitis in metastatic breast cancer: A case report
por: Chen, Guixian, et al.
Publicado: (2022)

Atezolizumab-Induced Sarcoidosis-Like Reaction in a Patient with Metastatic Breast Cancer
por: Tsunoda, Akira, et al.
Publicado: (2022)

Atezolizumab-induced psoriasis in a patient with metastatic lung cancer—a case report
por: Mao, Mian, et al.
Publicado: (2020)

Atezolizumab-induced encephalitis in metastatic lung cancer: a case report and literature review
por: Arakawa, Masafumi, et al.
Publicado: (2018)

Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report
por: Yamaguchi, Yoshitaka, et al.
Publicado: (2020)

Atezolizumab-induced encephalitis in a patient with metastatic breast cancer: a case report and review of neurological adverse events associated with checkpoint inhibitors
por: Nader, Rita, et al.
Publicado: (2021)

Atezolizumab induced immune-related adverse event mimicking conjunctival metastatic disease
por: Aschauer, Julia, et al.
Publicado: (2022)

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
por: Zhang, Xin, et al.
Publicado: (2021)

A Case Report of Atezolizumab Induced Tumor Lysis Syndrome
por: Fa’ak, Faisal, et al.
Publicado: (2019)

Atezolizumab-induced bilateral anterior uveitis: A case report
por: Mito, Tsuyoshi, et al.
Publicado: (2021)

When Does Transaminitis Become Acute Hepatic Failure? What Is the Management of Transaminitis and Acute Hepatic Failure?
por: Hieger, Michelle A.
Publicado: (2018)

Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer
por: Barrios, Carlos H., et al.
Publicado: (2022)

Cystoid Macular Edema following Treatment with Nanoparticle Albumin-Bound Paclitaxel and Atezolizumab for Metastatic Breast Cancer
por: Yamane, Hiroaki, et al.
Publicado: (2023)

A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma
por: Von, Cheong E, et al.
Publicado: (2021)

Atezolizumab: Drug-induced immune haemolytic anaemia: case report
Publicado: (2022)

Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab
por: Molinero, Luciana, et al.
Publicado: (2019)

Two Cases of Atezolizumab-Induced Hypophysitis
por: Kanie, Keitaro, et al.
Publicado: (2017)

Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
por: Liu, Xiaoyan, et al.
Publicado: (2021)

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?
por: Franzoi, Maria Alice, et al.
Publicado: (2020)

Atezolizumab (programmed cell death-ligand 1 antibody)-induced inflammation of actinic keratosis: A case report
por: Spitz, Kathleen E, et al.
Publicado: (2022)

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report
por: Yamakawa, Hideaki, et al.
Publicado: (2019)

ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
por: Kyte, J. A., et al.
Publicado: (2020)

Clinical trial-identified inflammatory biomarkers in breast and pancreatic cancers
por: Peng, Jing, et al.
Publicado: (2023)

Cholesterol as Carcinogen: I. Sarcoma Induction by Cholesterol in a Sensitive Strain of Mice II. Croton Oil a Complete Carcinogen
por: Hieger, I.
Publicado: (1962)

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
por: Emens, Leisha A, et al.
Publicado: (2021)

Atezolizumab Induces Necroptosis and Contributes to Hepatotoxicity of Human Hepatocytes
por: Endo, Yukinori, et al.
Publicado: (2023)

Atezolizumab-induced Encephalitis in a Patient with Hepatocellular Carcinoma: A Case Report and Literature Review
por: Satake, Tomoyuki, et al.
Publicado: (2022)

Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature
por: Feng, Dongfeng, et al.
Publicado: (2021)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Pericardial malignant infiltration as the cause of sudden death of a patient with metastatic urothelial carcinoma treated with atezolizumab
por: Palacka, Patrik, et al.
Publicado: (2022)

Atezolizumab Plus Bevacizumab-induced Recalcitrant Pyoderma Gangrenosum Treated with Baricitinib: A Case Report
por: KIM, Han Seul, et al.
Publicado: (2023)

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
por: Wallin, Jeffrey J., et al.
Publicado: (2016)

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
por: Facchinetti, Francesco, et al.
Publicado: (2018)

Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
por: Phua, Lee Cheng, et al.
Publicado: (2020)

SAT-475 New Breast Cancer Therapy Atezolizumab, Leads to Thyroiditis
por: Parimi, Joseph Theressa Nehu, et al.
Publicado: (2020)

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial
por: Mettu, Niharika B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pkr5cvqf5osl06d6km0j7bbqi2